The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here:

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Default user image.

Jan Apelqvist


Default user image.

Optimal wound closure of diabetic foot ulcers with early initiation of TLC-NOSF treatment : Post-hoc analysis of Explorer


  • José Luis Lázaro-Martínez
  • Michael Edmonds
  • Gerry Rayman
  • Jan Apelqvist
  • Kristien Van Acker
  • Agnès Hartemann
  • Jacques Martini
  • Ralf Lobmann
  • Serge Bohbot
  • Jean Charles Kerihuel
  • Alberto Piaggesi

Summary, in English

Objective: In March 2018, the Explorer study, an international, double-blind, randomised controlled trial (RCT), established that adding a TLC-NOSF (UrgoStart Contact, Laboratoires Urgo, France) dressing to good local standard of care (SoC) significantly and substantially increases wound closure and reduces the healing time of neuroischaemic diabetic foot ulcers (DFU). Besides the TLCNOSF treatment, the wound duration was the only other covariate that had an influence on the wound closure rate in the regression model used in the original study. The purpose of this work was to further document the impact of wound duration on the healing outcomes of the DFUs included in the Explorer study and to discuss complementary pragmatic observations on the TLC-NOSF effect. Method: In this post-hoc analysis of the Explorer data, the wound closure rates by week 20 are reported for the global cohort (n=240, Intention-to-treat population) and for the treated (n=126) and control groups (n=114) according to DFU duration and location. Results: For the combined group, wound closure rates decreased with the increase of wound duration at baseline (from 57% in wounds .2 months to 19% in wounds <11 months). Whatever the wound duration subgroups analysed, higher closure rates were reported in the TLC-NOSF group than in the control group. However, the maximal difference between the two treatments was reported in wounds with a duration of .2 months (71% versus 41%, 30 percentage points difference, Relative Risk 1.7, 95% Confidence Interval 1.1 to 2.8). Regarding wound location subgroup analyses, the outcomes were always in favour of the TLC-NOSF treatment, with closure rates ranging between 43% and 61% within the TLC-NOSF group, and between 25% and 40% within the control group. Conclusion: This clinical evidence supports that treating DFUs with TLC-NOSF dressing and good SoC results in higher wound closure rates than with a neutral dressing and the same good standard of care, whatever the duration and the location of the treated wounds. However, the earlier the TLC-NOSF dressing is initiated in DFU treatment, the greater the benefits. Declaration of interest: This study was supported by a grant from Laboratoires Urgo. S. Bohbot is an employee of Laboratoires Urgo. M. Edmonds, JL. Lazaro-Martinez, J. Martini, R. Lobmann and A. Piaggesi have received honoraria from the sponsor for being part of the trial Steering Committee and investigator coordinating tasks. A. Piaggesi and G. Rayman have received monetary compensation as speakers for Laboratoires Urgo. Data management and statistical analyses were conducted independently by Vertical.


  • EXODIAB: Excellence of Diabetes Research in Sweden

Publishing year







Journal of Wound Care





Document type

Journal article


Emap Healthcare Limited


  • Other Clinical Medicine


  • Diabetic foot ulcers
  • Randomised controlled trial
  • Sucrose octasulfate dressing
  • TLC-NOSF dressing
  • UrgoStart




  • ISSN: 0969-0700